The next step is for the CDC's Advisory Committee on Immunization Practices to make a decision on whether to add a COVID-19 booster to its recommendations
‘
As expected, the FDA has come out in a favor of a Pfizer COVID-19 vaccine shoot for people ages 65 and older and adults in highr isk groups
The agency followed the advice of an outside advisory committee, the Vaccines and Related Biological Products Advisory Committee, that voted last week for more limited use of the booster shot than had been envisioned by the Biden administration.
The FDA announced this evening that the agency had extended an emergency use authorization (EUA) for the Pfizer vaccine to allow a single booster shot to be given. The FDA said the booster shouldn’t be given till at least six months after the initial two-shot series of the Pfizer vaccine has been completed.
The drug regulator said booster can be given to people in three groups:
This summer, Biden administration floated the idea of all adults getting a booster, although it also indicated that it would follow the decisions of the and CDC.
The FDA’s EUA doesn’t set federal vaccine policy; the CDC’s Advisory Committee on Immunization Practices (ACIP) does. The ACIP committee met today to discuss the booster shoot and is scheduled to meet again tomorrow. According to the Associated Press, some of the members of the committee suggested putting off a decision for a month in hopes that more definitive evidence about the booster will become available.
Latest Vaccines and Antiviral Treatments Show Promising Results in Reducing Severe COVID Outcomes
March 7th 2024It was found in a recent study that the updated Moderna, Pfizer-BioNTech and Novavax COVID-19 vaccines, when combined with antiviral treatments like nirmatrelvir and molnupiravir, can significantly decrease the chances of hospitalization and death from current COVID-19 variants.
Read More
In this episode, Peter Wehrwein, managing editor of Managed Healthcare Executive, speaks with Dr. Rodrigo Cerda. Dr. Cerda has been recently promoted to the position of senior vice president of health services and chief medical officer of Independence Blue Cross in Philadelphia. He is also a member of Managed Healthcare Executive’s editorial advisory board. Peter and Dr. Cerda discuss his new role at the Independence Blue Cross, what it means to be a chief medical officer at an insurer these days, valued-based care, social determinants of health, and, of course, the pandemic.
Listen
How More Prompt Action Could Have Saved Thousands of U.S. COVID-19 Deaths
December 10th 2023Researchers of a study compared Israel's CVOID-19 booster rollout experience to the United States to ask the question: How many lives could the U.S. have saved if boosters were authorized sooner?
Read More
Briana Contreras, associate editor of MHE, spoke with Dr. Maria Hernandez, founder and CEO of Impact4Health. Maria shared not only how healthcare inequities remain to be an issue and what needs to be addressed, but also the progress that has been made over time through awareness, conversations and laws, especially due to the heightened awareness of inequities caused from the COVID-19 pandemic and the tragic deaths of George Floyd, Breonna Taylor and many more - which have now occurred over a year ago.
Listen
A Cup or Two of Joe a Day Could Keep COVID-19 Infection Away
November 19th 2023Coffee, rich in polyphenolic compounds like chlorogenic acid (CGA), caffeic acid (CAA), cafestol, melanoidins and trigonelline, has been recognized as a dominant source of CGA in various studies. Previous studies suggest that CGA in coffee can positively impact blood pressure, lipid profile, glycemia and insulin resistance.
Read More
The Challenges, Strategies of COVID-19 Misinformation Interventions
November 16th 2023COVID-19 misinformation interventions should involve public health experts, establish consistent outcome measures and more to address health misinformation at individual, community and systems levels, according researchers of a recent study.
Read More